Fibrocell launches anti-inflammatory pact with Intrexon; Halozyme inks $150M credit deal; Ohio biotech plots HQ move to San Diego

> Exton, PA-based Fibrocell Science ($FCSC) is teaming up with Intrexon ($XON) to develop genetically engineered fibroblasts to treat inflammatory conditions, with a special focus on arthritis. Fibrocell is handing over a $10 million tech access fee to get the partnership launched, with up to $52.5 million in development and commercial milestones for each new product that gets through to an approval. Fibrocell will also foot the bill for R&D. Release

> Halozyme Therapeutics ($HALO) inked a $150 million credit agreement after pledging royalties from its Enhanze products. Release

> The Ohio biotech Biosortia Pharmaceuticals is moving its HQ into J&J's ($JNJ) accelerator in San Diego after raising $500,000. Story

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.